Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma
| Autor: | Aliyah R. Sohani, Joycelynne Palmer, Alex F. Herrera, Yi-Bin Chen, Lihua E. Budde, Philippe Armand, Stephen J. Forman, Robert J. Soiffer, Christine Pak, Dennis D. Weisenburger, Amrita Krishnan, Jasmine Zain, Tanya Siddiqi, Wing C. Chan, Leslie Popplewell, Joseph H. Antin, Robert T. Chen, Liana Nikolaenko, John Koreth, Sarah Nikiforow, Dongyun Yang, Scott J. Rodig, German Pihan, Joyce Murata-Collins, Joo Y. Song, Matthew Mei, Larry W. Kwak, David M. Weinstock, Victoria Bedell, Corey Cutler, Auayporn Nademanee, Paola Dal Cin, Young L. Kim, Steven T. Rosen, Vincent T. Ho, Gabriel K. Griffin, Edwin P. Alyea, Raju Pillai |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Lymphoma B-Cell Mediastinal Neoplasms Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Refractory Internal medicine medicine Humans Survival rate Aged Retrospective Studies Transplantation business.industry Retrospective cohort study Hematology Middle Aged Allografts medicine.disease Leukemia Lymphocytic Chronic B-Cell Lymphoma Surgery Survival Rate 030220 oncology & carcinogenesis Cohort Female business Diffuse large B-cell lymphoma Stem Cell Transplantation 030215 immunology |
| Zdroj: | Biology of Blood and Marrow Transplantation. 24:514-520 |
| ISSN: | 1083-8791 |
| Popis: | Double-hit lymphomas (DHLs) and double-expressor lymphomas (DELs) are associated with resistance to frontline and salvage immunochemotherapy, as well as autologous stem cell transplantation (SCT). We hypothesized that allogeneic SCT (alloSCT) could overcome the chemoresistance associated with DEL/DHL. We retrospectively studied the impact of DEL/DHL status in a multicenter cohort of patients who underwent alloSCT for relapsed/refractory (rel/ref) aggressive B cell non-Hodgkin lymphoma (B-NHL). Seventy-eight patients transplanted at 3 centers in whom tumor tissue was available for immunohistochemistry and fluorescence in situ hybridization were enrolled; 47% had DEL and 13% had DHL. There were no significant differences in 4-year progression-free (PFS) or overall survival (OS) between patients with DEL compared with patients without DEL (PFS 30% versus 39%, P = .24; OS 31% versus 49%, P = .17) or between patients with DHL compared with patients without DHL (PFS 40% versus 34%, P = .62; OS 50% versus 38%, P = .46). The lack of association between DEL or DHL and outcome was confirmed in multivariable models, although inadequate sample size may have limited our ability to detect significant differences. In our cohort alloSCT produced durable remissions in patients with rel/ref aggressive B-NHL irrespective of DEL and DHL status, justifying its consideration in the treatment of patients with rel/ref DEL/DHL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect